Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arijit Ganguli

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Arthritis Research & Therapy|June 11, 2020
Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 26, 2013
A checklist for ascertaining study cohorts in oncology health services research using secondary data: report of the ISPOR oncology good outcomes research practices working groupKathy L Schulman, Karina Berenson, Ya-Chen Tina Shih, et al.
Journal of Drugs in Dermatology : JDD|December 1, 2018
Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based AnalysisJashin Wu, April Armstrong, Rakesh Singh, et al.
Advances in Therapy|July 31, 2012
Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritisYifei Liu, Eric Q Wu, Arielle G Bensimon, et al.
Dermatology and Therapy|August 18, 2017
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT RegistryAlan Menter, Diamant Thaçi, Jashin J Wu, et al.
Inflammatory Bowel Diseases|April 19, 2018
Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel DiseaseMarla C Dubinsky, Raymond K Cross, William J Sandborn, et al.
Journal of the American Academy of Dermatology|September 18, 2017
Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativaIltefat H Hamzavi, Murali Sundaram, Cynthia Nicholson, et al.
Cancers|December 10, 2021
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical TrialsBertrand Tombal, Arnulf Stenzl, David Cella, et al.
Eclinicalmedicine|August 21, 2025
Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysisStephen J Freedland, Ugo De Giorgi, Antti Rannikko, et al.
MDM Policy & Practice|November 12, 2025
Treatment Preferences among Patients with Hormone-Sensitive Prostate Cancer in France, Spain, China, South Korea, and Japan: A Discrete-Choice ExperimentJuan Marcos Gonzalez, Arijit Ganguli, Alicia K Morgans, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Arthritis Research & Therapy|June 11, 2020
Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 26, 2013
A checklist for ascertaining study cohorts in oncology health services research using secondary data: report of the ISPOR oncology good outcomes research practices working groupKathy L Schulman, Karina Berenson, Ya-Chen Tina Shih, et al.
Journal of Drugs in Dermatology : JDD|December 1, 2018
Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based AnalysisJashin Wu, April Armstrong, Rakesh Singh, et al.
Advances in Therapy|July 31, 2012
Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritisYifei Liu, Eric Q Wu, Arielle G Bensimon, et al.
Dermatology and Therapy|August 18, 2017
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT RegistryAlan Menter, Diamant Thaçi, Jashin J Wu, et al.
Inflammatory Bowel Diseases|April 19, 2018
Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel DiseaseMarla C Dubinsky, Raymond K Cross, William J Sandborn, et al.
Journal of the American Academy of Dermatology|September 18, 2017
Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativaIltefat H Hamzavi, Murali Sundaram, Cynthia Nicholson, et al.
Cancers|December 10, 2021
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical TrialsBertrand Tombal, Arnulf Stenzl, David Cella, et al.
Eclinicalmedicine|August 21, 2025
Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysisStephen J Freedland, Ugo De Giorgi, Antti Rannikko, et al.
MDM Policy & Practice|November 12, 2025
Treatment Preferences among Patients with Hormone-Sensitive Prostate Cancer in France, Spain, China, South Korea, and Japan: A Discrete-Choice ExperimentJuan Marcos Gonzalez, Arijit Ganguli, Alicia K Morgans, et al.
Pageof 7